Cipla Ltd.
Fundamentals
- Market cap
- ₹1.16 lakh cr
- P/E
- 29.99×
- ROE
- 11.27%
- Debt / equity
- 0.01
- Div yield
- 0.90%
- 52-week range
- 1165.70 — 1673.00
Company snapshot
Cipla Ltd.
Pharmaceuticals
₹1.14 L cr
P/E 33.79×
Latest quarter · Jun 2026
Sales₹7,119 cr
Net profit₹787 cr
Op. margin+16.8%
EPS₹9.77
Strength & growth
Debt / equity0.01×
Current ratio3.44×
Sales CAGR+7.6%
EPS CAGR+12.3%
The timeline — 4 notes on Cipla Ltd.
July 2026
- 27 Jul 26 · 10:56 PM IST Lead Lead · Mega cap
Cipla wins US FDA nod for generic Advair Diskus
The approval opens a $908M asthma/COPD market, with launch in Q2 FY27. A single Form 483 observation at the New York facility adds a small caveat.
- 27 Jul 26 · 5:14 PM IST Brief Brief · Earnings · Mega cap
Cipla posts ₹7,119 cr Q1 revenue, reiterates FY27 margin guidance
The transcript adds nothing new beyond the July 23 concall; numbers were already known. Key: India business grew 12%, US Ventolin launched, EBITDA margin target 18.5-20%.
- 18 Jul 26 · 9:35 AM IST Brief Brief · Mega cap
Cipla's InvaGen unit gets single USFDA observation, no warning letter
A routine cGMP inspection at the New York facility ended with one Form 483 observation. The outcome is minor compared to more severe regulatory actions.